The Centers for Disease Control and Prevention’s (CDC’s) vaccine advisory committee will meet on Tuesday for a two-day session to lay out new recommendations, including a proposal to scale back current COVID-19 vaccine guidelines.
Dr. Lakshmi Panagiotakopoulos of the CDC is expected to present guidance on COVID-19 vaccine use for 2025–2026 and suggest the department adopt a ‘narrow’ recommendation for it, ‘and only maintain this series for certain populations within these groups who we determine should be vaccinated.’
When polled on April 3, a majority of advisors – 76% – expressed support for a risk-based, rather than universal, COVID-19 vaccination recommendation for the 2025–2026 schedule, up 10% higher from February polling.
The 70-page presentation outlines three possible policy options for COVID-19 vaccines, including a shift away from recommending annual shots for everyone over 6 months old.
Currently, annual COVID-19 shots are recommended for ages 6 months and older. One proposed policy option would continue the current universal policy, while another would recommend vaccines only for people at higher risk of severe illness, such as older adults, those with underlying health conditions, pregnant women and healthcare workers.
A third option would blend the two, keeping universal recommendations for people 65 and older but limiting shots for younger groups to those at higher risk.
‘When initially presented with 2025–2026 COVID-19 vaccine policy options in November 2024, the Work Group appreciated pros and cons of both risk-based and universal vaccine recommendations,’ Panagiotakopoulos wrote. ‘At that time, there was not yet a consensus on what the recommendation for the 2025–2026 COVID-19 vaccine should be. The Work Group requested additional information to help inform the decision-making process on risk-factors for severe COVID-19, transmission and immunity, vaccine implementation and access, and cost-effectiveness.’
The presentation will also propose how to define ‘increased risk,’ looking at both health factors and increased exposure, like living in long-term care facilities or working in high-contact jobs.
The two-day meeting of the Advisory Committee on Immunization Practices will examine information for members to vote on as official recommendations, which will then be passed on to the CDC for consideration in June.
The end of the presentation will include discussion questions about the pros and cons of a universal vs. risk-based COVID-19 vaccine recommendation for 2025 to 2026. Key discussion points include whether any groups should be excluded from vaccination, what data is still needed to guide decisions, and whether a risk-based approach makes sense if most people are already considered ‘at risk.’
According to the CDC, the vaccine committee’s agenda will also include a session about the measles outbreak and an update ‘on literature related to reduced number of doses for HPV vaccine.’
Members of the committee will vote on Wednesday on recommendations for the Meningococcal Vaccines, Meningococcal Vaccines VFC, RSV Adult and the Chikungunya Vaccines.
The meeting comes as Health and Human Services Secretary Robert F. Kennedy Jr. is overseeing a major reorganization of the CDC. Plans include transferring non-infectious disease-related divisions to the Administration for a Healthy America to focus on chronic disease management. This move follows significant downsizing under President Donald Trump’s directive, which has already reduced the CDC workforce by roughly 4,000 people.
